強迫性障害(Obsessive-Compulsive Disorder):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Obsessive-Compulsive Disorder - Pipeline Review, H2 2014
◆商品コード:GMDHC5698IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における強迫性障害(Obsessive-Compulsive Disorder)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・強迫性障害(Obsessive-Compulsive Disorder)の概要
・強迫性障害(Obsessive-Compulsive Disorder)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・強迫性障害(Obsessive-Compulsive Disorder)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・強迫性障害(Obsessive-Compulsive Disorder)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・強迫性障害(Obsessive-Compulsive Disorder)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Obsessive-Compulsive Disorder – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Obsessive-Compulsive Disorder – Pipeline Review, H2 2014’, provides an overview of the Obsessive-Compulsive Disorder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Obsessive-Compulsive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Obsessive-Compulsive Disorder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Obsessive-Compulsive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Obsessive-Compulsive Disorder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Obsessive-Compulsive Disorder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Obsessive-Compulsive Disorder Overview 7
Therapeutics Development 8
Pipeline Products for Obsessive-Compulsive Disorder – Overview 8
Pipeline Products for Obsessive-Compulsive Disorder – Comparative Analysis 9
Obsessive-Compulsive Disorder – Therapeutics under Development by Companies 10
Obsessive-Compulsive Disorder – Therapeutics under Investigation by Universities/Institutes 11
Obsessive-Compulsive Disorder – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Obsessive-Compulsive Disorder – Products under Development by Companies 16
Obsessive-Compulsive Disorder – Products under Investigation by Universities/Institutes 17
Obsessive-Compulsive Disorder – Companies Involved in Therapeutics Development 18
AbbVie Inc. 18
Addex Therapeutics Ltd 19
C4X Discovery Ltd 20
F. Hoffmann-La Roche Ltd. 21
Heptares Therapeutics Ltd. 22
Novartis AG 23
Omeros Corporation 24
Rottapharm SpA 25
Sellas Inc. 26
Obsessive-Compulsive Disorder – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 33
Drug Profiles 34
ADX-71743 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ADX-88178 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
bitopertin – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CR-5542 Series – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CR-5772 Series – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
dipraglurant IR – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
fluvoxamine maleate – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
mavoglurant – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
methoxycoronaridine – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
OMS-527 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Inhibit DAT and SERT for CNS Disorders – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
zolpidem tartrate – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Obsessive-Compulsive Disorder – Recent Pipeline Updates 53
Obsessive-Compulsive Disorder – Dormant Projects 58
Obsessive-Compulsive Disorder – Discontinued Products 59
Obsessive-Compulsive Disorder – Product Development Milestones 60
Featured News & Press Releases 60
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

[List of Tables]
Number of Products under Development for Obsessive-Compulsive Disorder, H2 2014 8
Number of Products under Development for Obsessive-Compulsive Disorder - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Comparative Analysis by Unknown Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc., H2 2014 18
Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H2 2014 19
Obsessive-Compulsive Disorder - Pipeline by C4X Discovery Ltd, H2 2014 20
Obsessive-Compulsive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 21
Obsessive-Compulsive Disorder - Pipeline by Heptares Therapeutics Ltd., H2 2014 22
Obsessive-Compulsive Disorder - Pipeline by Novartis AG, H2 2014 23
Obsessive-Compulsive Disorder - Pipeline by Omeros Corporation, H2 2014 24
Obsessive-Compulsive Disorder - Pipeline by Rottapharm SpA, H2 2014 25
Obsessive-Compulsive Disorder - Pipeline by Sellas Inc., H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 33
Obsessive-Compulsive Disorder Therapeutics - Recent Pipeline Updates, H2 2014 53
Obsessive-Compulsive Disorder - Dormant Projects, H2 2014 58
Obsessive-Compulsive Disorder - Discontinued Products, H2 2014 59

[List of Figures]
Number of Products under Development for Obsessive-Compulsive Disorder, H2 2014 8
Number of Products under Development for Obsessive-Compulsive Disorder - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Top 10 Targets, H2 2014 28
Number of Products by Stage and Top 10 Targets, H2 2014 29
Number of Products by Top 10 Mechanism of Actions, H2 2014 30
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 31
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 32
Number of Products by Stage and Top 10 Molecule Types, H2 2014 33

【掲載企業】

AbbVie Inc.
Addex Therapeutics Ltd
C4X Discovery Ltd
F. Hoffmann-La Roche Ltd.
Heptares Therapeutics Ltd.
Novartis AG
Omeros Corporation
Rottapharm SpA
Sellas Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[強迫性障害(Obsessive-Compulsive Disorder):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆